Jeremy Bender, Day One Biopharmaceuticals CEO
June 13, 2022 11:28 AM EDTUpdated 12:08 PM
R&D

With pan-RAF drug from Take­da, Day One un­veils its first pe­di­atric brain can­cer da­ta. And the mar­ket loves it

Amber Tong

Day One Bio­phar­ma­ceu­ti­cals has gath­ered the first cut of Phase II da­ta on its quest to repo­si­tion a Take­da drug as a treat­ment for pe­di­atric …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ag­i­lent re­veals plans to re­mod­el op­er­a­tions as an­nu­al rev­enue dips

A service from the Financial Times